We are using our novel application of gene silencing technologies to build a focused product pipeline to address unmet medical needs across numerous indications, beginning first with Oculopharyngeal Muscular Dystrophy (OPMD) and Hepatitis B (HNV).
BB-301 is a late-stage nonclinical investigational agent currently in development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is the lead pipeline program for Benitec, and IND-enabling studies are currently being conducted.
BB-103 has demonstrated robust nonclinical activity during the evaluation of this agent for the treatment of Chronic Hepatitis B Virus infection. Benitec is currently seeking strategic partners to advance BB-103 through IND-enabling studies.
